Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051103 · ClinicalTrials.gov registry record · Phase 2
Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00051103: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT00051103 is a Phase 2 study that has completed, run by GlaxoSmithKline. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00051103, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to determine the efficacy of an oral investigational drug for the treatment of metastatic breast cancer tumors that are known to overexpress HER2/neu.
Interventions
- DRUG Investigational Cancer Drug
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-10 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
What the finished NCT00051103 record still lists
NCT00051103 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Investigational Cancer Drug is the first listed.
NCT00051103 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00051103 about?
NCT00051103 is a clinical study titled "Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.". The purpose of this study is to determine the efficacy of an oral investigational drug for the treatment of metastatic breast cancer tumors that are known to overexpress HER2/neu.
What is the current status of trial NCT00051103?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-10. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00051103?
The interventions under investigation include: Investigational Cancer Drug (DRUG).
Who is sponsoring clinical trial NCT00051103?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia